Analysts Expect Cascadian Therapeutics Inc (CASC) to Announce -$0.29 Earnings Per Share

Analysts expect that Cascadian Therapeutics Inc (NASDAQ:CASC) will report ($0.29) earnings per share for the current quarter, Zacks Investment Research reports. Zero analysts have provided estimates for Cascadian Therapeutics’ earnings. Cascadian Therapeutics posted earnings per share of ($0.47) during the same quarter last year, which indicates a positive year over year growth rate of 38.3%. The company is scheduled to issue its next earnings results on Thursday, March 8th.

According to Zacks, analysts expect that Cascadian Therapeutics will report full-year earnings of ($1.27) per share for the current fiscal year, with EPS estimates ranging from ($1.53) to ($1.14). For the next financial year, analysts anticipate that the business will report earnings of ($1.03) per share, with EPS estimates ranging from ($1.22) to ($0.69). Zacks’ EPS averages are an average based on a survey of sell-side analysts that that provide coverage for Cascadian Therapeutics.

Cascadian Therapeutics (NASDAQ:CASC) last announced its quarterly earnings data on Wednesday, November 8th. The biopharmaceutical company reported ($0.28) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.29) by $0.01. During the same period last year, the business earned ($0.09) earnings per share.

Separately, Zacks Investment Research lowered Cascadian Therapeutics from a “hold” rating to a “sell” rating in a report on Tuesday, January 9th. Three analysts have rated the stock with a sell rating, one has issued a hold rating and three have assigned a buy rating to the company. The stock currently has an average rating of “Hold” and a consensus target price of $5.63.

Several hedge funds have recently made changes to their positions in the company. OxFORD Asset Management LLP increased its holdings in shares of Cascadian Therapeutics by 11.8% in the second quarter. OxFORD Asset Management LLP now owns 181,323 shares of the biopharmaceutical company’s stock valued at $674,000 after purchasing an additional 19,131 shares during the period. SG Americas Securities LLC boosted its stake in shares of Cascadian Therapeutics by 194.7% in the fourth quarter. SG Americas Securities LLC now owns 38,541 shares of the biopharmaceutical company’s stock worth $143,000 after buying an additional 25,464 shares during the last quarter. New York State Common Retirement Fund purchased a new stake in shares of Cascadian Therapeutics in the second quarter worth about $136,000. Rhumbline Advisers purchased a new stake in shares of Cascadian Therapeutics in the second quarter worth about $143,000. Finally, Schwab Charles Investment Management Inc. purchased a new stake in shares of Cascadian Therapeutics in the second quarter worth about $225,000. 80.33% of the stock is currently owned by institutional investors and hedge funds.

Shares of Cascadian Therapeutics (NASDAQ CASC) traded up $0.23 during mid-day trading on Friday, hitting $5.15. The stock had a trading volume of 346,248 shares, compared to its average volume of 281,408. The firm has a market capitalization of $248.76, a price-to-earnings ratio of -3.81 and a beta of 2.30. Cascadian Therapeutics has a fifty-two week low of $3.18 and a fifty-two week high of $5.30.

TRADEMARK VIOLATION WARNING: “Analysts Expect Cascadian Therapeutics Inc (CASC) to Announce -$0.29 Earnings Per Share” was originally published by American Banking News and is the property of of American Banking News. If you are viewing this news story on another domain, it was illegally copied and republished in violation of U.S. and international copyright & trademark laws. The legal version of this news story can be accessed at https://www.americanbankingnews.com/2018/01/27/analysts-expect-cascadian-therapeutics-inc-casc-to-announce-0-29-earnings-per-share.html.

Cascadian Therapeutics Company Profile

Cascadian Therapeutics, Inc, formerly Oncothyreon Inc, is a clinical-stage biopharmaceutical company. The Company focuses on the development of therapeutic products for the treatment of cancer. The Company’s clinical-stage product candidate includes ONT-380, an orally active and selective small-molecule human epidermal growth factor receptor (HER) 2 inhibitor.

Get a free copy of the Zacks research report on Cascadian Therapeutics (CASC)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Cascadian Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cascadian Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply